Physician profile
Yolandra Johnson
NPI 1326030511
$4,498.17
in general payments reported to CMS, 2019-2025
26 companies · $642 in 2025
The $642 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $712 · 2021: $623 · 2022: $547 · 2023: $495 · 2024: $563 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606 · Education: $94.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.26 |
| Education | $94.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $920.51 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $886.51 | 2019-2025 | Entyvio, Gattex |
| Braintree Laboratories, INC. | $564.14 | 2019-2023 | Sutab |
| Abbvie INC. | $506.59 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.99 | 2019-2024 | Trulance, Xifaxan |
| Celltrion USA INC. | $124.06 | 2025 | Vegzelma |
| Pfizer INC. | $111.47 | 2023-2025 | |
| Allergan, INC. | $104.74 | 2019 | |
| Phathom Pharmaceuticals, INC. | $103.05 | 2024-2025 | Voquezna |
| Genzyme Corporation | $97.53 | 2023-2025 | |
| Ucb, INC. | $95.61 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $91.70 | 2019-2021 | |
| Celgene Corporation | $76.13 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $65.31 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $63.65 | 2019-2024 | Ocaliva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $51.91 | 2019-2020 | |
| Ardelyx, INC. | $49.65 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $47.76 | 2019-2021 | |
| Gilead Sciences, INC. | $44.49 | 2019-2020 | |
| Madrigal Pharmaceuticals | $37.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $23.34 | 2024 | Dupixent |
| Redhill Biopharma INC. | $20.52 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $18.95 | 2024 | Iqirvo |
| Enterra Medical, INC. | $17.77 | 2024 | |
| Lilly USA, LLC | $17.10 | 2024 | Omvoh |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolandra Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.